Charles Schwab Investment Management Inc. Buys 76,196 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Charles Schwab Investment Management Inc. boosted its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,989,340 shares of the biotechnology company's stock after acquiring an additional 76,196 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.65% of Iovance Biotherapeutics worth $14,721,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. acquired a new stake in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $12,927,000. Principal Financial Group Inc. boosted its stake in Iovance Biotherapeutics by 59.0% during the third quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company's stock worth $37,872,000 after buying an additional 1,496,941 shares in the last quarter. State Street Corp boosted its stake in Iovance Biotherapeutics by 4.6% during the third quarter. State Street Corp now owns 13,201,978 shares of the biotechnology company's stock worth $123,967,000 after buying an additional 576,801 shares in the last quarter. Barclays PLC increased its holdings in Iovance Biotherapeutics by 118.8% in the 3rd quarter. Barclays PLC now owns 604,584 shares of the biotechnology company's stock valued at $5,677,000 after buying an additional 328,284 shares during the period. Finally, Victory Capital Management Inc. raised its stake in shares of Iovance Biotherapeutics by 399.4% in the 3rd quarter. Victory Capital Management Inc. now owns 144,280 shares of the biotechnology company's stock valued at $1,355,000 after buying an additional 115,387 shares in the last quarter. Institutional investors and hedge funds own 77.03% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several analysts have recently weighed in on IOVA shares. Truist Financial decreased their target price on shares of Iovance Biotherapeutics from $25.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Robert W. Baird decreased their price objective on Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a report on Friday, February 28th. The Goldman Sachs Group dropped their target price on Iovance Biotherapeutics from $22.00 to $19.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Chardan Capital decreased their price target on Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Finally, Piper Sandler lowered their price target on Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating on the stock in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $20.25.

Iovance Biotherapeutics Stock Up 2.5 %

IOVA stock traded up $0.09 during midday trading on Monday, reaching $3.63. 6,695,664 shares of the company's stock traded hands, compared to its average volume of 6,970,929. The company has a 50-day simple moving average of $5.12 and a two-hundred day simple moving average of $7.75. Iovance Biotherapeutics, Inc. has a 1-year low of $3.42 and a 1-year high of $15.50. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -2.44 and a beta of 0.93.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.26). The company had revenue of $73.69 million during the quarter, compared to analyst estimates of $72.17 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. Equities research analysts forecast that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.